A quantitative reverse-transcriptase PCR assay for the assessment of drug activities against intracellular Theileria annulata schizonts

Isabel Hostettler, Joachim Müller, Chad E. Stephens, Richard Haynes, Andrew Hemphill

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Intracellular schizonts of the apicomplexans Theileria annulata and Theileria parva immortalize bovine leucocytes thereby causing fatal immunoproliferative diseases. Buparvaquone, a hydroxynaphthoquinone related to parvaquone, is the only drug available against Theileria. The drug is only effective at the onset of infection and emerging resistance underlines the need for identifying alternative compounds. Current drug assays employ monitoring of proliferation of infected cells, with apoptosis of the infected host cell as a read-out, but it is often unclear whether active compounds directly impair the viability of the parasite or primarily induce host cell death. We here report on the development of a quantitative reverse transcriptase real time PCR method based on two Theileria genes, tasp and tap104, which are both expressed in schizonts. Upon in vitro treatment of T. annulata infected bovine monocytes with buparvaquone, TaSP and Tap104 mRNA expression levels significantly decreased in relation to host cell actin already within 4. h of drug exposure, while significant differences in host cell proliferation were detectable only after 48-72. h. TEM revealed marked alterations of the schizont ultrastructure already after 2. h of buparvaquone treatment, while the host cell remained unaffected. Expression of TaSP and Tap104 proteins showed a marked decrease only after 24. h. Therefore, the analysis of expression levels of mRNA coding for TaSP and Tap104 allows to directly measuring impairment of parasite viability. We subsequently applied this method using a series of compounds affecting different targets in other apicomplexan parasites, and show that monitoring of TaSP- and Tap104 mRNA levels constitutes a suitable tool for anti-theilerial drug development.

Original languageEnglish (US)
Pages (from-to)201-209
Number of pages9
JournalInternational Journal for Parasitology: Drugs and Drug Resistance
Volume4
Issue number3
DOIs
StatePublished - Dec 1 2014

Fingerprint

Theileria annulata
Schizonts
Reverse Transcriptase Polymerase Chain Reaction
Theileria
Parasites
Pharmaceutical Preparations
Messenger RNA
Theileria parva
Cell Proliferation
Actins
Real-Time Polymerase Chain Reaction
Monocytes
Leukocytes
Cell Death
Apoptosis
Infection
Genes
buparvaquone
Proteins

Keywords

  • Apicomplexa
  • Apoptosis
  • Chemotherapy
  • Electron microscopy
  • Real time PCR
  • Theileria
  • Theileriosis

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

A quantitative reverse-transcriptase PCR assay for the assessment of drug activities against intracellular Theileria annulata schizonts. / Hostettler, Isabel; Müller, Joachim; Stephens, Chad E.; Haynes, Richard; Hemphill, Andrew.

In: International Journal for Parasitology: Drugs and Drug Resistance, Vol. 4, No. 3, 01.12.2014, p. 201-209.

Research output: Contribution to journalArticle

@article{42f45de2964a436aa60947c6fae983ec,
title = "A quantitative reverse-transcriptase PCR assay for the assessment of drug activities against intracellular Theileria annulata schizonts",
abstract = "Intracellular schizonts of the apicomplexans Theileria annulata and Theileria parva immortalize bovine leucocytes thereby causing fatal immunoproliferative diseases. Buparvaquone, a hydroxynaphthoquinone related to parvaquone, is the only drug available against Theileria. The drug is only effective at the onset of infection and emerging resistance underlines the need for identifying alternative compounds. Current drug assays employ monitoring of proliferation of infected cells, with apoptosis of the infected host cell as a read-out, but it is often unclear whether active compounds directly impair the viability of the parasite or primarily induce host cell death. We here report on the development of a quantitative reverse transcriptase real time PCR method based on two Theileria genes, tasp and tap104, which are both expressed in schizonts. Upon in vitro treatment of T. annulata infected bovine monocytes with buparvaquone, TaSP and Tap104 mRNA expression levels significantly decreased in relation to host cell actin already within 4. h of drug exposure, while significant differences in host cell proliferation were detectable only after 48-72. h. TEM revealed marked alterations of the schizont ultrastructure already after 2. h of buparvaquone treatment, while the host cell remained unaffected. Expression of TaSP and Tap104 proteins showed a marked decrease only after 24. h. Therefore, the analysis of expression levels of mRNA coding for TaSP and Tap104 allows to directly measuring impairment of parasite viability. We subsequently applied this method using a series of compounds affecting different targets in other apicomplexan parasites, and show that monitoring of TaSP- and Tap104 mRNA levels constitutes a suitable tool for anti-theilerial drug development.",
keywords = "Apicomplexa, Apoptosis, Chemotherapy, Electron microscopy, Real time PCR, Theileria, Theileriosis",
author = "Isabel Hostettler and Joachim M{\"u}ller and Stephens, {Chad E.} and Richard Haynes and Andrew Hemphill",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.ijpddr.2014.09.003",
language = "English (US)",
volume = "4",
pages = "201--209",
journal = "International Journal for Parasitology: Drugs and Drug Resistance",
issn = "2211-3207",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - A quantitative reverse-transcriptase PCR assay for the assessment of drug activities against intracellular Theileria annulata schizonts

AU - Hostettler, Isabel

AU - Müller, Joachim

AU - Stephens, Chad E.

AU - Haynes, Richard

AU - Hemphill, Andrew

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Intracellular schizonts of the apicomplexans Theileria annulata and Theileria parva immortalize bovine leucocytes thereby causing fatal immunoproliferative diseases. Buparvaquone, a hydroxynaphthoquinone related to parvaquone, is the only drug available against Theileria. The drug is only effective at the onset of infection and emerging resistance underlines the need for identifying alternative compounds. Current drug assays employ monitoring of proliferation of infected cells, with apoptosis of the infected host cell as a read-out, but it is often unclear whether active compounds directly impair the viability of the parasite or primarily induce host cell death. We here report on the development of a quantitative reverse transcriptase real time PCR method based on two Theileria genes, tasp and tap104, which are both expressed in schizonts. Upon in vitro treatment of T. annulata infected bovine monocytes with buparvaquone, TaSP and Tap104 mRNA expression levels significantly decreased in relation to host cell actin already within 4. h of drug exposure, while significant differences in host cell proliferation were detectable only after 48-72. h. TEM revealed marked alterations of the schizont ultrastructure already after 2. h of buparvaquone treatment, while the host cell remained unaffected. Expression of TaSP and Tap104 proteins showed a marked decrease only after 24. h. Therefore, the analysis of expression levels of mRNA coding for TaSP and Tap104 allows to directly measuring impairment of parasite viability. We subsequently applied this method using a series of compounds affecting different targets in other apicomplexan parasites, and show that monitoring of TaSP- and Tap104 mRNA levels constitutes a suitable tool for anti-theilerial drug development.

AB - Intracellular schizonts of the apicomplexans Theileria annulata and Theileria parva immortalize bovine leucocytes thereby causing fatal immunoproliferative diseases. Buparvaquone, a hydroxynaphthoquinone related to parvaquone, is the only drug available against Theileria. The drug is only effective at the onset of infection and emerging resistance underlines the need for identifying alternative compounds. Current drug assays employ monitoring of proliferation of infected cells, with apoptosis of the infected host cell as a read-out, but it is often unclear whether active compounds directly impair the viability of the parasite or primarily induce host cell death. We here report on the development of a quantitative reverse transcriptase real time PCR method based on two Theileria genes, tasp and tap104, which are both expressed in schizonts. Upon in vitro treatment of T. annulata infected bovine monocytes with buparvaquone, TaSP and Tap104 mRNA expression levels significantly decreased in relation to host cell actin already within 4. h of drug exposure, while significant differences in host cell proliferation were detectable only after 48-72. h. TEM revealed marked alterations of the schizont ultrastructure already after 2. h of buparvaquone treatment, while the host cell remained unaffected. Expression of TaSP and Tap104 proteins showed a marked decrease only after 24. h. Therefore, the analysis of expression levels of mRNA coding for TaSP and Tap104 allows to directly measuring impairment of parasite viability. We subsequently applied this method using a series of compounds affecting different targets in other apicomplexan parasites, and show that monitoring of TaSP- and Tap104 mRNA levels constitutes a suitable tool for anti-theilerial drug development.

KW - Apicomplexa

KW - Apoptosis

KW - Chemotherapy

KW - Electron microscopy

KW - Real time PCR

KW - Theileria

KW - Theileriosis

UR - http://www.scopus.com/inward/record.url?scp=84908311955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908311955&partnerID=8YFLogxK

U2 - 10.1016/j.ijpddr.2014.09.003

DO - 10.1016/j.ijpddr.2014.09.003

M3 - Article

VL - 4

SP - 201

EP - 209

JO - International Journal for Parasitology: Drugs and Drug Resistance

JF - International Journal for Parasitology: Drugs and Drug Resistance

SN - 2211-3207

IS - 3

ER -